Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Minoryx Therapeutics and Gain Therapeutics announce today the spin off of the Minoryx Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform into Gain Therapeutics, a new company that will focus on using this platform to identify the next generation of non-competitive pharmacological chaperones.
Gain Therapeutics, funded by private Swiss investors and by the TiVenture fund has its headquarters in Lugano (Switzerland), with a branch operating from Barcelona (Spain). Researchers from the Minoryx laboratory at the Barcelona Science Park joined the new spin-off, under the scientific management of Dr Xavier Barril, ICREA researcher and co-founder of Minoryx Therapeutics, inventor of the technology.
This new spin-off is part of Minoryx’s business strategy, in order to concentrate the company's efforts on the clinical candidate MIN-102.
“This deal validates the SEE-Tx platform and its great potential for identifying a new generation of pharmacological chaperones with improved properties,” said Dr Marc Martinell, co-founder and CEO of Minoryx Therapeutics. “It will also allow Minoryx to focus on its clinical candidate, MIN-102, which is now in phase II/III clinical trials for the treatment of X-linked adrenoleukodystrophy and in preclinical development for other orphan CNS diseases.”
“We are delighted to build on the excellent work done by Minoryx’s team. Using the SEE-Tx platform, it has already identified molecules that have the potential to become novel therapies for the treatment of several devastating rare diseases,” said Dr Lorenzo Leoni, managing partner of TiVenture and ad-interim CEO of Gain Therapeutics. “We will invest in the further development of these molecules that should lead to the identification of clinical candidates in at least two independent programs. We are also happy to strengthen the cooperation between Barcelona and southern Switzerland, two regions with high innovation potential in the biomedical field.”
Gain Therapeutics, funded by private Swiss investors and by the TiVenture fund has its headquarters in Lugano (Switzerland), with a branch operating from Barcelona (Spain). Researchers from the Minoryx laboratory at the Barcelona Science Park joined the new spin-off, under the scientific management of Dr Xavier Barril, ICREA researcher and co-founder of Minoryx Therapeutics, inventor of the technology.
This new spin-off is part of Minoryx’s business strategy, in order to concentrate the company's efforts on the clinical candidate MIN-102.
“This deal validates the SEE-Tx platform and its great potential for identifying a new generation of pharmacological chaperones with improved properties,” said Dr Marc Martinell, co-founder and CEO of Minoryx Therapeutics. “It will also allow Minoryx to focus on its clinical candidate, MIN-102, which is now in phase II/III clinical trials for the treatment of X-linked adrenoleukodystrophy and in preclinical development for other orphan CNS diseases.”
“We are delighted to build on the excellent work done by Minoryx’s team. Using the SEE-Tx platform, it has already identified molecules that have the potential to become novel therapies for the treatment of several devastating rare diseases,” said Dr Lorenzo Leoni, managing partner of TiVenture and ad-interim CEO of Gain Therapeutics. “We will invest in the further development of these molecules that should lead to the identification of clinical candidates in at least two independent programs. We are also happy to strengthen the cooperation between Barcelona and southern Switzerland, two regions with high innovation potential in the biomedical field.”
